{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:41:32Z","timestamp":1791942092179,"version":"4.3.4"},"reference-count":0,"publisher":"The Journal of Rheumatology","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study examined the effect of dose step-down in patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib 4 mg once daily for up to 96 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who completed a baricitinib phase III study could enter a long-term extension (LTE). In the LTE, patients who received baricitinib 4 mg for \u2265 15 months and maintained Clinical Disease Activity Index (CDAI) low disease activity (LDA) or remission (REM) were blindly randomized to continue with 4 mg or taper to 2 mg. If needed, 2-mg\u2013treated patients could be rescued to 4 mg, and 4-mg\u2013treated patients could be rescued by adding or increasing conventional synthetic disease-modifying antirheumatic drugs. Efficacy and safety were assessed through 96 weeks. Nonresponder imputation (NRI), considering rescued or discontinued patients as nonresponders, was used for CDAI response analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At 96 weeks, most patients maintained LDA in both 2-mg and 4-mg arms, with a lower maintenance rate in the 2-mg than the 4-mg group (NRI 59.9% and 70.2%, respectively). Patients maintained REM in the 2-mg and 4-mg arms at 30.8% and 36.6%, respectively. Rescue rates were 14.7% for baricitinib 4 mg and 22.5% for 2 mg. Of 112 patients who lost LDA in the 2-mg arm and were rescued to 4 mg, 76.2% and 75.6% achieved LDA again at 12 and 24 weeks postrescue, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In a randomized, blinded, phase III LTE study, maintenance of disease control following induction of sustained LDA\/REM with baricitinib 4 mg was greater with continued 4 mg than after tapering to 2 mg. Nonetheless, 76% of patients tapered to 2 mg could maintain LDA\/REM or recapture with return to 4 mg, if needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2024-0906","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T08:20:59Z","timestamp":1736929259000},"page":"jrheum.2024-0906","source":"Crossref","is-referenced-by-count":5,"title":["Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results From the RA-BEYOND Study"],"prefix":"10.3899","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8233-6602","authenticated-orcid":false,"given":"Christopher J.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-4325","authenticated-orcid":false,"given":"Gerhard","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2463-218X","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Avouac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2590-6242","authenticated-orcid":false,"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1897-049X","authenticated-orcid":false,"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8070-7062","authenticated-orcid":false,"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daojun","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Haladyj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7302-8692","authenticated-orcid":false,"given":"Masaru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Takita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Hagimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-8218","authenticated-orcid":false,"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,1,15]]},"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-0906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T08:25:20Z","timestamp":1738398320000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-0906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":0,"alternative-id":["10.3899\/jrheum.2024-0906"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-0906","relation":{},"ISSN":["0315-162X","1499-2752","0315-162X"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"},{"value":"0315-162X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,15]]}}}